Melatonin: A "Higgs boson" in human reproduction

Gynecological Endocrinology

Volumn 31, Issue 2, 2015, Pages 92-101

  Dikic, Svetlana Dragojevic ^a   Jovanovic, Ana Mitrovic ^a   Dikic, Srdjan ^a,b   Jovanovic, Tomislav ^a,c   Jurisic, Aleksandar ^a   Dobrosavljevic, Aleksandar ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b University Medical Center Bezanijska Kosa   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Cancer; Immune function; Melatonin; Reproductive function; Reproductive health

Indexed keywords

MELATONIN; MELATONIN RECEPTOR;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MENOPAUSE; OOCYTE; OVARY FOLLICLE CELL; PREGNANCY; PRIORITY JOURNAL; PUBERTY; REPRODUCTION; REPRODUCTIVE HEALTH; CIRCADIAN RHYTHM; MALE; METABOLISM; OVARY FOLLICLE; PHYSIOLOGY; PINEAL BODY;

CIRCADIAN RHYTHM; EMBRYONIC DEVELOPMENT; FEMALE; HUMANS; MALE; MELATONIN; OVARIAN FOLLICLE; PINEAL GLAND; PREGNANCY; PUBERTY; REPRODUCTION;

EID: 84921328337     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.978851     Document Type: Article

References (134)

1. Cho A. The discovery of the Higgs boson. Science 2012;338: 1524-5.
2. Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80:2587-92.
3. Brzezinski A. Melatonin in humans. New Engl J Med 1997;336: 186-95.
4. Pang SF, Allen AE. Extra-pineal melatonin in the retina: its regulation and physiological function. Pineal Res Rev 1986;4:55-96.
5. Slominski A, Wortsman J, Tobin, DJ. The cutaneous serotoninergic/ melatoninergic system securing a place under sun. FASEB J 2005; 19:176-94.
6. Bubenik GA. Gastrointestinal melatonin: localisation, function and clinical relevance. Dig Dis Sci 2002;47:2336-48.
7. Conti A, Conconi S, Hertens S, et al. Evidence of melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000;28:193-202.
8. Carrillo-Vicco A, Calvo JR, Abreu P, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role in intracrine, autocrine, and/or paracrine substance. FASEB J 2004;18:537-9.
9. Korkmaz A, Manchester LC. Reactive nitrogen species; devastating intracellular players and melatonin as a defender. J Exp Integr Med 2011;1:63-5.
10. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003;34:75-8.
11. Gillette MU, Tischkau SA. Suprachiasmatic nucleus: the brain's circadian clock. Recent Prog Horm Res 1999;54:33-58.
12. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-80.
13. Cardinali DP, Pevet P. Basic aspects of melatonin action. Sleep Med Rev 1998;2:175-90.
14. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens Suppl 2009;27:17-20.
15. Srinivasan V, Maestroni GJ, Cardinali DP, et al. Melatonin, immune function and aging. Immun Ageing 2005;2:1-10.
16. Korkmaz A, Tamura H, Manchester IC, et al. Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line. J Pineal Res 2009;46:115-16.
17. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
18. Brzezinski A, Seibel MM, Lynch HJ, et al. Melatonin in human preovulatory follicular fluid. J Clin Endocrinol Metab 1987;64: 865-7.
19. Tamura H, Nakamura Y, Takiguchi S, et al. Pinealectomy of melatonin implantation does not affect prolactin surge or lutal function in pseudopregnant rats. Endocr J 1998; 45:377-83.
20. Tamura H, Nakamura Y, Trron MP, et al. Melatonin and pregnancy in the human. Reprod Toxicol 2008;25:291-303.
21. Hattori A. The basic information for melatonin. Mod Physician 2007;27:1053-6.
22. Yonei Y, Hattori A, Tsutsui K, et al. Effects of melatonin: basic studies and clinical applications. Anti-aging Med 2010;7:85-91.
23. Pang SF, Li L, Ayre EA, et al. Neuroendocrinology of melatonin n in reproduction: recent developments. J Clin Neuroanatomy 1998;14: 157-66.
24. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002;295: 1070-3.
25. Gerdin MJ, Masana MI, Rivera-Bermudez MA, et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus. Relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 2004;18:1646-56.
26. Reiter RJ, Gultekin F, Flores LJ, et al. Melatonin: potential utility for improving public health. TAF Prev Med Bull 2006;5:131-58.
27. Dullo P, Chaudhary R. Short review of reproductive physiology of melatonin. Pak J Physiol 2009;5:46-8.
28. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-10.
29. Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275: 31311-17.
30. Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcrition factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 1998;12:143-50.
31. Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006;40:1-9.
32. Calberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000; 917:387-96.
33. Ishii H, Tanaka N, Kobayashi M. Gene structures, biochemical characterization and distribution of rat melatonin receptors. J Physiol Sci 2009;59:37-47.
34. Srinivasan V, Spence WD, Pandi-Perumal SR, et al. Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol 2009;25:779-85.
35. Boczek-Leszczyk E, Juszczak M. The influence of melatonin on human reproduction. Pol Merkur Lekarski 2007;23:128-30.
36. Wojtowicz M, Jakiei G. Melatonin and its role in human reproduction. Ginekol Pol 2002;73:1231-7.
37. Maganhin CC, Carbonel AA, Hatty JH, et al. Melatonin effects on the female genital system: a brief review. Rev Assoc Med Bras 2008; 54:267-71.
38. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008;85:335-53.
39. Zemkova H, Vanecek J. Inhibitory effect of melatonin on gonado-trophin- releasing hormone induced Ca2+ oscillations in pituitary cells of newborn rats. Neuroendocrinology 1997;65:276-83.
40. Malpaux B, Migaud M, Tricoire R, Chemineau P. Biology of mammalian photoperiodism and the critical role of pineal gland and melatonin. J Biol Rhytms 2001;16:336-47.
41. Bentley GE, Ubuka T, McGuire NL, et al. GnRH: a multifunctional neuropeptide. J Neuroendocrinol 2009;21: 276-8.
42. Silman RE. Melatonin and the human gonadotrophin-releasing hormone pulse generator. J Endocrinol 1991;128:7-11.
43. Waldhauser F, Boepple PA, Schemper M, et al. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal. J Clin Endocrinol Metab 1991;73:793-6.
44. Cavallo A. Melatonin and human puberty: current perspectives. J Pineal Res 1993;15:115-21.
45. Brzezinski A. Melatonin and human reproduction: why the effect is so elusive? In: Pandy-Perumal SR, Cardinali DP, eds. Melatonin: from molecules to therapy. New York: Nova Science Publishers; 2007:219-25.
46. Reiter RJ, Tan DX, Manchester LC, et al. Melatonin and reproduction revised. Biol Reprod 2009;81:445-56.
47. Richards JS, Panges SA. The ovary: basic biology and clinical implications. J Clin Invest 2010;120:963-72.
48. Soares Jr JM, Masana MI, Ersahin C, Dubovich ML. Functional melatonin receptors in rat ovaries at various stages of th estrous cycle. J Pharmacol Exp Ther 2003;306:694-702.
49. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res 2010;181:127-51.
50. Tamura H, Nakamura Y, Korkmaz A, et al. Melatonin and the ovary: physiological and pathological implications. Fertil Steril 2009;92: 328-43.
51. Tan DX, Manchester LC, Terron MP, Reiter RJ. One molecule, many derivates: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007;42:28-42.
52. Tamura H, Takasaki A, Taketani T, et al. Melatonin as free radical scavenger in the ovarian follicle. Endocr J 2013;60:1-13.
53. Tamura H, Nakamura Y, Terron MP, et al. Melatonin and pregnancy in the human. Reprod Toxicol 2008;25:291-303.
54. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 1994;50:233-8.
55. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
56. Hensley K, Robinson KA, Gabbita SP, et al. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28:1456-62.
57. Fetehi AN, Roelen BA, Colenbrander B, et al. Presence of cumulus cells during in vitro fertilization protects the bovine oocyte against oxidative stress and improves first cleavage but does not affect further development. Zygote 2005;13:177-85.
58. Tatemoto H, Muto N, Sunagawa I, et al. Protection of porcine oocytes against cell damage caused by oxidative stress during in vitro maturation: role of superoxide dismutase activity in porcine follicular fluid. Biol Reprod 2004;71:1150-7.
59. Guerin P, El Mouatassim S, Menezo Y. Oxidative stress and protection against reactive oxygen species in the preimplantation embryo and its surroundings. Hum Reprod Update 2001;7:175-89.
60. Ishizuka B, Kuribayashi Y, Murai K, et al. The effect of melatonin on in vitro fertilization and embryo development in mice. J Pineal Res 2000;28:48-51.
61. Tamura H, Takasaki A, Taketani T, et al. The role of melatonin as an antioxidant in the follicle. J Ovarian Res 2012;5:1-9.
62. Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocyte from free radical damage and improves fertilization rates. J Pineal Res 2008;44: 280-7.
63. Walsh SW, Wang Y. Secretion of lipid peroxides by the human placenta. Am J Obstet Gynecol 1993;169:1462-6.
64. Mover-Lev H, Ar A. Changes in enzymatic antioxidant activity in pregnant rats exposed to hyperoxia. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1997;118:353-9.
65. Milczarek R, Klimek J, Zelewski L. Melatonin inhibits NADPHdependent lipid peroxidation in human placental mitochondria. Horm Metab Res 2000;32:84-5.
66. Nagai R, Watanabe K, Wakatsuki A, et al. Melatonin preserves fetal growth in rats by protecting against ischemia/reperfusion-induced oxidative/nitrosative mitochondrial damage in the placenta. J Pineal Res 2008;45:271-6.
67. Nakamura Y, Tamura H, Kashida S, et al. Changes of serum melatonin level and its relationship to fetoplacental unit during pregnancy. J Pineal Res 2001;30:29-33.
68. Shenker S, Yang Y, Perez A, et al. Antioxidant transport by the human placenta. Clin Nutr 1998;17:159-67.
69. Thomas L, Purvis CC, Drew JE, et al. Melatonin receptors in human fetal brain: 2-[(125)I]iodomelatonin binding and MT1 gene expression. J Pineal Res 2002;33:218-24.
70. Okatani Y, Watanabe K, Hayashi K, et al. Melatonin inhibits vasospastic action of hydrogen peroxide in human umbilical artery. J Pineal Res 1997;22:163-8.
71. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and the diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:9-14.
72. Fait V, Sela S, Ophir E, et al. Hyperemesis gravidarum is associated with oxidative stress. Am J Perinatol 2002;19:93-8.
73. Myatt L, Cui X. Oxidative stress in placenta. Histochem Cell Biol 2004;122:369-82.
74. Vanderlelie J, Venardos K, Clifton VL, et al. Increased biological oxidation and reduced anti-oxidant enzyme activity in pre-eclamptic placentae. Placenta 2005;26:53-8.
75. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42:319-22.
76. Pagni CA, Zenga F. Posttraumatic epilepsy with special emphasis on prophylaxis and prevention. Acta Neurochir Suppl 2005;93:27-34.
77. Gupta S, Agarwai A, Banerjee J, Alvarez JG. The role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: a systematic review. Obstet Gynecol Surv 2007;62:335-47.
78. Nakamura Y, Tamura H, Kashida S, et al. Changes of serum melatonin level and its relationship to feto-placental unit during pregnancy. J Pineal Res 2001;30:29-33.
79. Sharkey JT, Puttaramu R, Word RA, Olcese J. Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells. J Clin Endocrinol Metab 2009;94:421-7.
80. Carlomagno G, Nordio M, Chiu TT, Unfer V. Contribution of myoinositol and melatonin to human reproduction. Eur J Obstet Gynecol Reprod Biol 2012;159:267-72.
81. WHO Scientific Group. Research on the Menopause in the 1990s. WHO Technical Report Series No 866. Geneva:WHO; 1996.
82. Pines A, Sturdee DW, MacLennan AH, et al. The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric 2007;10:267-9.
83. Anderson E, Hamburger S, Liu JH, Rebr RW. Characteristics of menopausal women seeking assistance. Am J Obstet Gynecol 1987; 156:428-33.
84. Williams RE, Levine KB, Kalilani L, et al. Menopause-specific questionnaire assessment in US population-based studz shows negative impact on health-related quality of life. Maturitas 2009; 62:153-9.
85. Pollycove R, Naftolin F, Simon JA. The evolutionary origin and significance of menopause. Menopause 2011;18:336-42.
86. Archer DF, Baber RJ, Barlow D, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-20.
87. De Villiers TJ, Gass MLS, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16: 203-4.
88. Bellipani G, Marzo F, Blasi F, Di Marzo A. Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann N Y Acad Sci 2005;1057:393-402.
89. Satomura K, Tobiume S, Tokuyama R, et al. Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 2007;42:231-9.
90. Reiter RJ, Korkmaz A. Clinical aspects of melatonin. Saudi Med J 2008;29:1537-47.
91. Rodriguez MI, Escames G, López L, et al. Chronic melatonin treatment reduces the age-dependent inflammatory process in senescence-accelerated mice. J Pineal Res 2007;42:272-9.
92. Masilamoni JG, Jesudason EP, Dhandayuthapani S, et al. The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radical Res 2008;42:661-73.
93. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 2005;16:254-8.
94. Girgert R, Hanf V, Emons G, Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 2009;47:23-31.
95. Jan JE, Reiter RJ, Wasdell MB, Bax M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res 2009;46:1-7.
96. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta analysis. Sleep Med Rev 2005;9:41-50.
97. Srinivasan V, Cardinali DP, Pandi-Perumal SR, Brown GM. Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integr Med 2011;1:149-58.
98. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults chronic insomnia. Sleep Med 2006;7:312-18.
99. Guillenminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients of major depressive disorder. Eur Neuropsychopharmacol 2005;15:419-20.
100. Burnet M. Somatic mutation and chronic disease. Br Med J 1965;1: 338-42.
101. Cardinalli DP, Esquino AI, Srinivasan V, Pandi-Perumal SR. Melatonin and the immune system in aging. Neuroimmunomodulation 2008;15:272-8.
102. Nelson RJ, Drazen DL. Melatonin mediates seasonal changes in immune function. Ann N Y Acad Sci 2000;917:404-15.
103. Lardone PJ, Carrillo-Vico A, Naranjo MC, et al. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physyiol 2006;206:273-9.
104. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytes and monocytic cell lines. J Pineal Res 2000;29:129-37.
105. Currier NL, Sun LZ, Miller SC. Exogenous melatonin: quantitative enhancement in vivo of cells mediating non.specific immunity. J Neuroimmunol 2000;104:101-8.
106. Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res 1994;54:2429-32.
107. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science 1981;214:24-30.
108. Garcia-Maurino S, Gonzales-Haba MG, Calvo JR, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997;159:574-81.
109. Jiang H, Chess L. An integrated view of suppresor T cell subset in immunoregulation. J Clin Invest 2004;114:1198-208.
110. Ossendorp F, Toes RE, Offringa R, et al. Importance of CD4+ T helper cell responses in tumor immunity. Immunol Lett 2000;74: 75-9.
111. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
112. Raghavendra V, Singh V, Kulkarni SK, Agrewala JN. Melatonin enhances Th-2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiapine receptor antagonist. Mol Cell Biochem 2001;221:57-62.
113. Srinivasan V, Pandi-Perumal SR, Brzezinski A, et al. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 2011;5:109-23.
114. Karbownik M, Lewinski A, Reiter RJ. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol 2001;33:735-53.
115. Karbownik M, Reiter RJ, Burkhardt S, et al. Melatonin attenuates estradiol-induced oxidative damage to DNA: relation to cancer prevention. Exp Biol Med 2001;226:707-12.
116. Reiter RJ. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative disease. Neuroendocrinol Lett 2002;23:9-13.
117. Vijayalaxmi Dr, Thomas Jr CR, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-601.
118. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 2005;27: 179-88.
119. Mills F, Wu P, Seely D, Guyott G. Melatonin in the treatment of cancer: a systematic review of randomized trials and meta-analysis. J Pineal Res 2005;39:360-6.
120. Cabrera J, Negrin G, Estevez F, et al. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010;49:45-54.
121. Karasek M, Kowalski AJ, Zylinska K. Serum melatonin circadian profile in women suffering from the genital tract cancers. Neuro Endocrinol Lett 2000;21:109-13.
122. Winczyk K, Fuss-Chmielewska J, Lawnicka H, et al. Luzindole but not 4-phenyl-2-propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. Neuroendocrinol Lett 2009;30:657-62.
123. Molis TM, Spriggs LL, Jupiter Y, Hill SM. Melatonin modulation of estrogen-related proteins, growth factors, and proto-oncogenesis in human breast cancer. J Pineal Res 1995;18:93-103.
124. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84.
125. Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther 2009;8:347-53.
126. Anisimov VN, Popovich IG, Zabezhinski MA, et al. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochem Biophys Acta 2006;1757:573-89.
127. Greider CW, Blackburn EH. Identification of specific telomere terminal transferase activity in tetrahymena extracts. Cell 1985;43: 405-13.
128. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005;3:309-14.
129. Kilic E, Kilic U, Reiter RJ, et al. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 2004;37: 247-51.
130. Schernhammer ES, Berrino F, Krough V, et al. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010;19:729-37.
131. Bartsch C, Bartsch H, Jain AK, et al. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981;52: 281-94.
132. Sanchez-Barcelo EJ, Cos S, Mediavilla D, et al. Melatoninestrogen interactions in breast cancer. J Pineal Res 2005;38: 217-22.
133. Cos S, Gonzalez A, Martinez-Campa C, et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 2008;8:691-702.
134. Reiter JR, Rosales-Corral AS, Manchester CL, Tan DX. Peripheral reproductive organ health and melatonin: ready for prime time. Int J Mol Sci 2013;14:7231-72.